Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 807 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Group B Clear all
Completed Phase 1 Interventional

A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

NCT00519480
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Metformin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

NCT01751646
View directory record Official record
Conditions
HIV Infection
Interventions
Vitamin D3 50,000 IU, Vitamin D3 placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

NCT00636168
View directory record Official record
Conditions
High Risk Stage III Melanoma
Interventions
ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebos
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 8, 2026, 8:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772
View directory record Official record
Conditions
Coeliac Disease, Celiac Disease
Interventions
Amlitelimab, Placebo, SIGE, Gluten-free product (GFP)
Drug · Dietary Supplement
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Scottsdale, Arizona • Arcadia, California • Lancaster, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

NCT06186219
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Rituximab
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese

NCT01679028
View directory record Official record
Conditions
Healthy
Interventions
T89 Group A, Placebo Group A, Placebo Group B, T89 Group B, Placebo Group C, T89 Group C
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 8, 2026, 8:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

NCT02505542
View directory record Official record
Conditions
Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1Phase 2 Interventional

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

NCT02718495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PTI-428, Placebo
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery

NCT05528172
View directory record Official record
Conditions
Corneal Edema After Cataract Surgery
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

NCT06270836
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Tarcocimab, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

NCT07636811
View directory record Official record
Conditions
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Interventions
Mivelsiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
40 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Maitland, Florida • Naples, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

NCT06605599
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Dothan, Alabama • Anaheim, California • Colton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

NCT07772531
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BMS-986511, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581
View directory record Official record
Conditions
Asthma
Interventions
PF-07275315, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Mobile, Alabama • Chandler, Arizona • Lancaster, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Recruiting No phase listed Observational

Study Evaluating the Quality and Effects of Lion's Mane Product on Cognitive Health

NCT06870136
View directory record Official record
Conditions
Cognitive Decline
Interventions
Lion's Mane Study Product
Dietary Supplement
Lead sponsor
M2 Ingredients
Industry
Eligibility
40 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 8, 2026, 8:05 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

NCT07772921
View directory record Official record
Conditions
Asthma
Interventions
tilrekimig, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Garland, Texas • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

NCT06373146
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Gardena, California • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

NCT03922607
View directory record Official record
Conditions
Psoriasis
Interventions
ABBV-157, Placebo for ABBV-157
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 8, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

NCT02110706
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 8, 2026, 8:05 PM EDT